TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25926408
Drug: Coarse+LBG treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coarse+LBG treatment (larger, 6-μm mean droplet size with 0.5% locust bean gum)
Study: 21343383
Drug: THC (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (2.5 mg, Marinol(®), twice daily for 18 days)
Study: 18781875
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Meningococcal conjugate vaccine against serogroup C)
Study: 25424793
Drug: 7-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-valent pneumococcal conjugate vaccine (PCV7)
Study: 16359793
Drug: Gabapentin-morphine combination
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin-morphine combination
Study: 12666979
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose doxycycline (20 mg, b.i.d.)
Study: 16044962
Drug: MMC +
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC + HCFU (300 mg/day orally for one year)
Study: 3551972
Drug: TAD consolidation
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD consolidation with monthly maintenance chemotherapy
Study: 26818127
Drug: Tripterygium glycoside
Normalized name: anthraquinone glycoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripterygium glycoside (TPT), 2 pills three times daily for 2 months
Study: 30870291
Drug: Intravenous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous furosemide 10 mg
Study: 1565347
Drug: 5-mg PGE2
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-mg PGE2 gel
Study: 1776748
Drug: HP 128
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 128 (adrenergic/cholinergic agent) administered for 10 days
Study: 27265548
Drug: First-generation antipsychotics
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotics (FGAs) - haloperidol (3-6 mg) or flupentixol (6-12 mg)
Study: 19916263
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulsed dye laser (PDL) with compression handpiece (CHP), 6 J/cm2, 6 msec pulse duration, three monthly treatments
Study: 15591642
Drug: Ketoprofen administered
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen administered one hour before incision (PRE group)
Study: 25872773
Drug: Cascade intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cascade intervention (online cognitive-behavioural therapy)
Study: 9109825
Drug: NaF rinse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaF rinse (12 mmol/L, 228 ppm)
Study: 9314342
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite avoidance treatment
Study: 10996576
Drug: Salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmon calcitonin nasal spray 200 IU
Study: 22412114
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy
Study: 8738770
Drug: Caffeine citrate
Normalized name: Caffeine Citrate
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine citrate 3 mg/kg, 15 mg/kg, or 30 mg/kg administered once daily for 7 days
Study: 15898977
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with depigmented glutaraldehyde-polymerized extracts (Group-A)
Study: 22968811
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of ketoconazole after St John's wort induction
Study: 17617285
Drug: Guanfacine extended-release
Normalized name: Guanfacine Extended-Release Tablets
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guanfacine extended-release (GXR) 4 mg
Study: 1827125
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day spironolactone
Study: 30952488
Drug: Hydroxyurea 20
Normalized name: hydroxyurea 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea 20 mg/kg/day
Study: 17390549
Drug: Quinapril 10
Normalized name: quinapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 10 mg
Study: 17967675
Drug: parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: parecoxib 20 mg (IV) twice daily (n = 211)
Study: 7931615
Drug: Reduced-dose craniospinal
Normalized name: Iron, reduced
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose craniospinal radiotherapy (2400 cGy).
Study: 16492212
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine + insulin lispro
Study: 12932068
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia (TIVA) (Group TIVA)
Study: 23716037
Drug: Odanacatib 25
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 25 mg
Study: 19874198
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg
Study: 23019990
Drug: Positive barium
Normalized name: barium
DrugBank: Barium (DB12481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive barium sulphate suspension (900 ml, 2.1% w/v)
Study: 30605396
Drug: Heat therapy
Normalized name: CVS Neck Arm & Leg Heat Therapy Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat therapy (HT)
Study: 16424795
Drug: Lercanidipine 20
Normalized name: lercanidipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lercanidipine 20 mg/d for 15 days
Study: 10702763
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg per os, once a day
Study: 22797645
Drug: 420-mg silymarin
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 420-mg silymarin
Study: 1672843
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg slow-release isosorbide-5-mononitrate (IS-5-MN) after a 7-day therapy
Study: 20071293
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy with gemcitabine and cisplatin
Study: 14585937
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (continuous intravenous infusion)
Study: 9793283
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment modalities
Study: 21542988
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) treated group
Study: 18711765
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine therapy (TCM)
Study: 15170148
Drug: Post-chemotherapy assessment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-chemotherapy assessment
Study: 22585232
Drug: THC 15
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 15 mg
Study: 7633988
Drug: Intravenous pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentoxifylline infusion therapy, 600 mg twice daily for up to 21 days
Study: 6404377
Drug: Bedtime administration
Normalized name: Buckley's Bedtime Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedtime administration of intermediate acting insulin
Study: 26810282
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with HDM allergen extract
Study: 7000089
Drug: Colestipol hydrochloride
Normalized name: Colestipol Hydrochloride
DrugBank: Colestipol (DB00375)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colestipol hydrochloride (5 g X 3)
Study: 24297946
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg/day
Study: 17399871
Drug: Trapeziectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapeziectomy with flexor carpi radialis suspension
Study: 17464604
Drug: Infiltration around
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration around the hip joint with a mixture of 100 mL ropivacaine 2 mg/mL, 1 mL ketorolac 30 mg/mL, and 1 mL epinephrine 0.5 mg/mL (group A)
Study: 11409559
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml of bupivacaine 0.5% with epinephrine 0.0005%
Study: 15114087
Drug: Alemtuzumab (Campath-1H)
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab (Campath-1H) and low-dose Tacrolimus (Tac)
Study: 31686255
Drug: High-power therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-power therapeutic ultrasound with 5% lipolytic active caffeine gel (phonophoresis)
Study: 21779579
Drug: 133 mg
Normalized name: glycine 133 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 133 mg caffeine
Study: 9265993
Drug: Low hypnotic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low hypnotic susceptible subjects
Study: 17443649
Drug: nab-paclitaxel 10
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 10 mg/m2
Study: 17443649
Drug: nab-paclitaxel 30
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 30 mg/m2
Study: 25886254
Drug: Minocycline 100
Normalized name: minocycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline 100 mg modified-release capsules for 12 months
Study: 10755239
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg/week
Study: 24656609
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg or 300 mg subcutaneous daclizumab HYP every 4 weeks for 52 weeks (treatment initiation group)
Study: 15094269
Drug: Nevirapine 400
Normalized name: nevirapine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 400 mg once daily
Study: 15094269
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg twice daily
Study: 24342768
Drug: Intravenous application
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of 50 μg CCK-4
Study: 27090218
Drug: Sardine-enriched diet
Normalized name: sardine allergenic extract
DrugBank: European pilchard (DB10622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sardine-enriched diet (100 g of sardines 5 days a week for 6 months)
Study: 772669
Drug: Triprolidine 2.5
Normalized name: triprolidine 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triprolidine 2.5 mg
Study: 2894219
Drug: Dipipanone 8
Normalized name: dipipanone
DrugBank: Dipipanone (DB01491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipipanone 8 mg
Study: 2100659
Drug: Cathode Iontophoresis
Normalized name: Sumatriptan Iontophoretic Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cathode Iontophoresis using Sodium Fluoride solution (2%)
Study: 23978944
Drug: G-CSF post-chemotherapy
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF post-chemotherapy
Study: 26840038
Drug: Low fasting
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fasting blood glucose (<70 mg/dL)
Study: 10547245
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of OspA vaccine
Study: 9293831
Drug: Transfusions to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusions to maintain hemoglobin level of 10 g/dL
Study: 8984939
Drug: 240 U
Normalized name: tyrothricin 240 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 U kg‐1 r‐hu‐Epo subcutaneously, initially three doses weekly
Study: 23051883
Drug: Ultraport zero
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultraport zero stopcock without hub disinfection before injection
Study: 2688531
Drug: Ioxaglate 320
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate 320 mgI/ml
Study: 28481050
Drug: Bifocal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifocal treatment of myopia (3-year duration)
Study: 19650932
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 30 mg
Study: 14980929
Drug: Diazepam 10
Normalized name: diazepam 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 10 mg orally (DiazG)
Study: 14980929
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 microg intrathecally (Clon(i/t)G)
Study: 14980929
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 microg orally (Clon(p/o)G)
Study: 31044654
Drug: Art therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Art therapy (AT)
Study: 9773865
Drug: Daily ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily ganciclovir
Study: 9773865
Drug: 3-times-weekly ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-times-weekly ganciclovir
Study: 30721234
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention comprising clinical guidelines, monthly prescribing review meetings, doctor‐patient communication skills training, and education materials for caregivers.
Study: 25130768
Drug: Hot moisturizing
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot moisturizing formulation
Study: 21375092
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (2 ml, 4 mg)
Study: 16816554
Drug: Apricitabine 400
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Apricitabine 400 mg/day
Study: 11564594
Drug: Subcutaneous IL-2
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous IL-2 at either 4.5 MIU or 7.5 MIU q12h for 5 days every 8 weeks
Study: 9784909
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of propionyl-L-carnitine (IV bolus, 30 mg/kg body weight)
Study: 29655624
Drug: Routine immunizations
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine immunizations (DTwP-HepB-Hib, oral polio, pneumococcal conjugate 7 vaccines)
Study: 9415234
Drug: Topical 5-aminolaevulinic
Normalized name: methyl 5-aminolevulinate Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5-aminolaevulinic acid photodynamic therapy
Study: 23669304
Drug: Antacid (Antagel)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (Antagel)
Study: 19114704
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg every 2 weeks
Study: 19262464
Drug: Prescription label
Normalized name: Last Refill For This Prescription Label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription label reading skills
Study: 31435005
Drug: Increased urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased urinary phosphorus excretion
Study: 21301812
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg hydrocortisone
Study: 21301812
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg hydrocortisone
Study: 16612708
Drug: Vasopressin injections
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vasopressin injections (10 pmol/kg bw)
Study: 7564362
Drug: Piretanide monotherapy
Normalized name: piretanide
DrugBank: Piretanide (DB02925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide monotherapy
Study: 23645323
Drug: Ramipril monotherapy
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril monotherapy
Study: 15453924
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m2 I.V. weekly for 4 doses (n = 70)
Study: 10829313
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy combined with surgery
Study: 29221491
Drug: Gantenerumab 105
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab 105 mg
Study: 16237479
Drug: Cannabinoid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid therapy
Study: 6837336
Drug: Ethanol ingestion
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol ingestion (1.75 g/kg within 3 hours)
Study: 17954367
Drug: Olmesartan 10
Normalized name: amlodipine-olmesartan 10 mg-20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan 10 mg/day
Study: 19714275
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with modified Hagie pin
Study: 15008768
Drug: Incremental infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Incremental infusion of oxytocin discontinued at 5 cm dilation (Group B)
Study: 7724111
Drug: Oral sulindac
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sulindac (200 mg, once orally every 12 hours for 7 days)
Study: 2684077
Drug: methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone acetate (20 mg) intrabursal injection and oral naproxen (1 g/d for 10 days)
Study: 2684077
Drug: methylprednisolone acetate
Normalized name: methylprednisolone acetate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methylprednisolone acetate (20 mg) intrabursal injection and oral placebo for 10 days
Study: 30698725
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) 0 g protein
Study: 29277353
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (PHiD-CV 4-dose and 1-dose)
Study: 8966494
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplements (1.2 g of calcium and 800 IU of vitamin D3)
Study: 30845291
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + Amoxicillin + Metronidazole, each 500 mg, three times daily, for seven days (test group)
Study: 25573533
Drug: Olaparib 100
Normalized name: olaparib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib 100 mg b.i.d. (intermittent dosing; capsules) plus gemcitabine 600 mg/m(2)
Study: 9688014
Drug: Continuous fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous fluconazole at 200 mg/day
Study: 7805084
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody inhibitors to platelet membrane glycoprotein IIb/IIIa
Study: 31950948
Drug: GTE-CUR drink
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GTE-CUR drink (17.3 and 35.5 mg EGCG equivalent)
Study: 6846738
Drug: Budesonide treatment
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide treatment for 1 week
Study: 31487573
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) delivered as therapist-guided bibliotherapy
Study: 21982325
Drug: Water-based exercise
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Water-based exercise program (12 weeks, twice weekly)
Study: 19297572
Drug: CMV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV vaccine
Study: 19082528
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (calcium supplement plus menatetrenone)